Menu
Search
|

Menu

Close
X

ArQule Inc ARQL.OQ (NASDAQ Stock Exchange Global Market)

5.21 USD
+0.09 (+1.76%)
As of 1:30 AM IST
chart
Previous Close 5.12
Open 5.05
Volume 250,437
3m Avg Volume 444,199
Today’s High 5.24
Today’s Low 4.98
52 Week High 7.21
52 Week Low 0.94
Shares Outstanding (mil) 71.17
Market Capitalization (mil) 80.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
0
FY16
5
FY15
11
EPS (USD)
FY18
-0.075
FY17
-0.392
FY16
-0.326
FY15
-0.219
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
33.37
5.73
Price to Book (MRQ)
vs sector
7.97
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
143.04
16.84
LT Debt to Equity (MRQ)
vs sector
143.04
12.51
Return on Investment (TTM)
vs sector
-91.39
14.61
Return on Equity (TTM)
vs sector
-120.33
16.34

EXECUTIVE LEADERSHIP

Patrick Zenner
Independent Chairman of the Board, Since 2004
Salary: --
Bonus: --
Peter Lawrence
President, Chief Operating Officer, Since 2008
Salary: $413,921.00
Bonus: $158,325.00
Paolo Pucci
Chief Executive Officer, Director, Since 2008
Salary: $489,345.00
Bonus: $249,566.00
Robert Weiskopf
Chief Financial Officer, Treasurer, Since 2015
Salary: --
Bonus: --
Brian Schwartz
Chief Medical Officer, Since 2008
Salary: $394,597.00
Bonus: $134,761.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Wall St
BURLINGTON   MA   01803-4769

Phone: +1781.9940300

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

SPONSORED STORIES